149 related articles for article (PubMed ID: 30253727)
1. A severe case of bevacizumab-induced thrombotic microangiopathy.
Bektas M; Samancı NS; Cokgezer S; Keskin D; Demirelli FH
J Oncol Pharm Pract; 2019 Oct; 25(7):1754-1757. PubMed ID: 30253727
[TBL] [Abstract][Full Text] [Related]
2. Renal thrombotic microangiopathy caused by bevacizumab.
Horino T; Ichii O; Shimamura Y; Terada Y
Nephrology (Carlton); 2018 Apr; 23(4):378-379. PubMed ID: 29520904
[No Abstract] [Full Text] [Related]
3. Bevacizumab-associated glomerular microangiopathy.
Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
[TBL] [Abstract][Full Text] [Related]
4. A case of bevacizumab-induced non-remitting thrombotic microangiopathy.
Wong YHS; Sinniah R; Rosman J
Intern Med J; 2020 Nov; 50(11):1432-1434. PubMed ID: 33215823
[No Abstract] [Full Text] [Related]
5. Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literature.
Hilburg R; Geara AS; Qiu MK; Palmer MB; Chiang EY; Burger RA; Hogan JJ
Clin Nephrol; 2021 Jul; 96(1):51-59. PubMed ID: 33896447
[TBL] [Abstract][Full Text] [Related]
6. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-induced thrombotic microangiopathy and nephrotic syndrome.
Shimamura Y; Maeda T; Takizawa H
Clin Exp Nephrol; 2019 Jan; 23(1):142-143. PubMed ID: 29882112
[No Abstract] [Full Text] [Related]
8. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer.
Morimoto M; Arai T; Matsuura M; Ono Y
CEN Case Rep; 2021 Feb; 10(1):6-11. PubMed ID: 32642991
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous ulcer with thrombogenic vasculopathy in a patient receiving bevacizumab.
Vila-Payeras A; Iglesias-González M; Terrasa-Sagristá F; Parera-Amer E
Indian J Dermatol Venereol Leprol; 2021; 87(2):268-270. PubMed ID: 33769753
[No Abstract] [Full Text] [Related]
11. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye.
Schraermeyer U; Julien S
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1303-13. PubMed ID: 22614910
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?
Izzedine H; Sène D; Hadoux J; Gharbi C; Bourry E; Massard C; Soria JC
Ann Oncol; 2011 Feb; 22(2):487-90. PubMed ID: 21278225
[No Abstract] [Full Text] [Related]
14. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
16. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
Eremina V; Quaggin SE
Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
[TBL] [Abstract][Full Text] [Related]
17. [Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants].
Senellart H; Bennouna J
Rev Mal Respir; 2008 Oct; 25(8):1027-30. PubMed ID: 18971808
[TBL] [Abstract][Full Text] [Related]
18. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
19. Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol.
Baysal M; Ümit EG; Sarıtaş F; Kodal NS; Demir AM
Balkan Med J; 2018 Sep; 35(5):398-399. PubMed ID: 29687787
[TBL] [Abstract][Full Text] [Related]
20. Drug induced thrombotic microangiopathy caused by levofloxacin.
Kazi S; Preston GC
J R Coll Physicians Edinb; 2018 Jun; 48(2):127-129. PubMed ID: 29992202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
